Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
BackgroundIn breast cancers, only a minority of patients fully benefit from the different chemotherapy regimens currently in use.Identification of magnets markers that could predict the response to a particular regimen would thus be critically important for patient care.In cell lines or animal models, tumor protein p53 (TP53) plays a critical role